Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical Immunologymedical mutual - ohio Dawnzera Coverage Update | O…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Dawnzera (donidalorsen) — prophylaxis of hereditary angioedema (HAE)

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior-authorization, coverage criteria, dosing, and administrative requirements for Dawnzera (donidalorsen) used as prophylaxis of hereditary angioedema (HAE) for patients age ≥12, for Medical Mutual - Ohio members when billed under the medical or pharmacy benefit.

    Policy Summary
    Payermedical mutual - ohio
    PolicyDawnzera (donidalorsen) — prophylaxis of hereditary angioedema (HAE)
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateNov 20, 2025
    Last ReviewMar 19, 2026
    Next Review DateMar 19, 2026
    Key ActionSubmit prior authorization with documentation of diagnosis, baseline C1‑INH function and serum C4, prior prophylactic therapies tried, and prescriber specialty.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥12
    min age
    80 mgdose
    1 yrapproval duration
    J3490/J3590/J9999medical benefit codes

    Coverage criteria for Dawnzera (donidalorsen)

    HAE Prophylaxis — Initial and Continuation Therapy

    Approve Dawnzera for 1 year if the patient meets ONE of the following (A or B):

    A or B: A) Initial therapy OR B) Currently receiving Dawnzera

    A) Initial therapy

    • i-ii diagnostic and age: i. Patient is ≥ 12 years of age; AND ii. Patient has HAE type I or II confirmed by: a) low functional C1-INH (< 50% of normal) at baseline; AND b) low serum C4 at baseline

      HAE with normal C1-INH (type III) does NOT satisfy this requirement.

    • iii prescriber: iii. Medication prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders

      Initial approval requires prescription by or consultation with a specialist.

    • iv prior therapies: iv. Patient has tried two other therapies for prophylaxis of HAE (examples: Andembry, Cinryze, Haegarda, Oladeyo, Takhzyro)

    B) Patient currently receiving Dawnzera

    • i diagnosis: i. Patient has diagnosis of HAE type I or II (HAE type III does NOT satisfy)
    • ii response: ii. According to the prescriber, the patient has had a favorable clinical response since initiating Dawnzera prophylactic therapy (e.g., decreased attack frequency, severity, or duration)
    • iii prescriber: iii. Medication prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders

      If patient is currently receiving therapy but has not previously received approval, review under Initial Therapy criteria.

    The policy advises against concomitant long-term use of Dawnzera with other hereditary angioedema (HAE) prophylactic therapies because combination long-term prophylactic therapy has not been studied and therefore is not recommended. Short-term or procedural prophylaxis and on-demand treatments for acute HAE attacks (for example, intravenous C1 esterase inhibitor) remain acceptable as clinically indicated.

    Use of Dawnzera for indications not listed in the policy’s Recommended Authorization Criteria is not recommended and may be considered not medically necessary. Coverage decisions are limited to the circumstances described in the criteria and will be updated only as new published data become available.

    Coding and clinical thresholds

    Prior-authorization required HCPCS codes when Dawnzera is billed under medical benefitHCPCSCovered
    J3490Unclassified drugs
    J3590Unclassified biologics
    J9999Unclassified antineoplastics
    C1‑INH functional level — threshold value for diagnosis
    Threshold for functional C1-INH< 50% of normal (functional C1-INH protein at baseline)
    ContextRequired as part of diagnostic confirmation for HAE type I or II when seeking Dawnzera for prophylaxis
    Laboratory referenceMeasured against laboratory reference values at baseline as specified by the testing laboratory
    Age relevanceApplied when patient is ≥ 12 years of age per initial therapy criteria
    Role in prior authorizationDocumentation of baseline C1-INH functional level is required for approval of initial therapy

    Provider requirements, prior authorization, and documentation

    Prior Authorization

    Prior authorization required for medical benefit

    Prior authorization is required when Dawnzera is billed under the medical benefit using unclassified drug/biologic/antineoplastic HCPCS codes J3490, J3590, or J9999; requests meeting policy criteria may be authorized by a nurse reviewer, otherwise routed to a physician reviewer.

    • Applies when Dawnzera is billed under the medical benefit
    • HCPCS codes: J3490, J3590, J9999
    • Nurse reviewer may authorize if submitted documentation meets policy; otherwise forwarded to physician reviewer
    Step Therapy

    Prior trials required before initial therapy

    Initial therapy approval requires documented prior trials of two other therapies for HAE prophylaxis (examples provided in the policy include Andembry, Cinryze, Haegarda, Oladeyo, and Takhzyro).

    • Two prior prophylactic therapies must have been tried before initiating Dawnzera

    Background on Dawnzera (donidalorsen)

    Dawnzera (donidalorsen) is a prekallikrein‑directed antisense oligonucleotide indicated for the prophylaxis of hereditary angioedema (HAE) attacks in patients aged 12 years and older. It is intended for long‑term prophylaxis to reduce the frequency, severity, or duration of HAE attacks and should be prescribed or managed by a clinician experienced in HAE care.

    Definitions and diagnostic thresholds

    HAE type I or II — diagnostic definition
    Diagnostic definition for HAE type I or IIHereditary angioedema due to C1‑INH deficiency confirmed by low functional C1‑INH protein (<50% of normal) at baseline AND low serum C4 levels at baseline.
    ExclusionHAE with normal C1‑INH (also known as HAE type III) does NOT satisfy this requirement.
    Age requirementApplies for patients aged ≥ 12 years when used for initial therapy of HAE prophylaxis.
    Documentation neededBaseline laboratory results (functional C1‑INH and serum C4) must be provided to support diagnosis for prior authorization.
    Use in continuationFor patients currently receiving Dawnzera, a confirmed diagnosis of HAE type I or II is required for continuation approval.
    Policy Summary
    Payermedical mutual - ohio
    PolicyDawnzera (donidalorsen) — prophylaxis of hereditary angioedema (HAE)
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateNov 20, 2025
    Last ReviewMar 19, 2026
    Next Review DateMar 19, 2026
    Key ActionSubmit prior authorization with documentation of diagnosis, baseline C1‑INH function and serum C4, prior prophylactic therapies tried, and prescriber specialty.
    SourceLink
    On This Page
    Coverage criteria for Dawnzera (donidalorsen)Coding and clinical thresholdsProvider requirements, prior authorization, and documentationBackground on Dawnzera (donidalorsen)Definitions and diagnostic thresholds
  1. Examples listed: Andembry, Cinryze, Haegarda, Oladeyo, Takhzyro
  2. Requirement does not apply if patient is currently receiving Dawnzera
  3. Documentation Required

    Required documentation to support medical necessity

    Providers must provide documentation supporting the diagnosis and baseline laboratory values, records of prior therapies tried, and evidence of clinical response for renewals; the Company may request patient records, test results, and provider credentials.

    • Diagnosis documentation: confirmation of HAE type I or II with baseline C1‑INH functional level and baseline serum C4
    • Record of prior prophylactic therapies tried (for initial therapy)
    • For continuation, documentation of favorable clinical response since initiating Dawnzera
    Denial Risk

    Denial risks for lack of medical necessity or documentation

    The Company may deny reimbursement or require write-off if the drug or services are determined not medically necessary, investigational/experimental, not within benefit scope, or if requested documentation is not provided; claims with HCPCS J3490, J3590, J9999 will pend and may be denied as not medically necessary.

    • Claims with HCPCS J3490, J3590, J9999 will pend with remark codes and may be denied
    • A participating provider may be required to write off charges denied as not medically necessary
    • Additional documentation must be made available upon request to avoid denial